Drugmakers Think Blockchains Could Improve Clinical Trials
Three big pharmaceutical firms—Pfizer, Amgen, and Sanofi—are working together to use blockchains to speed up clinical tests of new drugs, according to CoinDesk.
The problem: Patient data that’s crucial to locating individuals for clinical trials is usually scattered across multiple proprietary systems that are often incompatible with each other. That can make it hard to recruit for trials.
How blockchains could help: A distributed ledger could allow individual patients to store data anonymously and make it visible to trial recruiters, who could then reach out to individuals who meet the eligibility criteria for a given trial. It could also streamline communication between doctors and patients during the trial.
It’s still early: Technologists are still mostly experimenting with blockchain-based medical records systems, and big technical challenges remain. The health-care industry is also heavily regulated and tends to be risk averse, which could impede adoption.
Keep Reading
Most Popular
This new data poisoning tool lets artists fight back against generative AI
The tool, called Nightshade, messes up training data in ways that could cause serious damage to image-generating AI models.
The Biggest Questions: What is death?
New neuroscience is challenging our understanding of the dying process—bringing opportunities for the living.
Rogue superintelligence and merging with machines: Inside the mind of OpenAI’s chief scientist
An exclusive conversation with Ilya Sutskever on his fears for the future of AI and why they’ve made him change the focus of his life’s work.
How to fix the internet
If we want online discourse to improve, we need to move beyond the big platforms.
Stay connected
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.